Lower risk for serious adverse events and no increased risk for cancer after PBSC vs BM donation

Blood

Volumn 123, Issue 23, 2014, Pages 3655-3663

  Pulsipher, Michael A ^a   Chitphakdithai, Pintip ^b   Logan, Brent R ^c   Navarro, Willis H ^b,d   Levine, John E ^e   Miller, John P ^d   Shaw, Bronwen E ^f   O'Donnell, Paul V ^g   Majhail, Navneet S ^b,h   Confer, Dennis L ^b,d  

^a UNIVERSITY OF UTAH SCHOOL OF MEDICINE   (United States)

^b CENTER FOR INTERNATIONAL BLOOD AND MARROW TRANSPLANT RESEARCH   (United States)

^c MEDICAL COLLEGE OF WISCONSIN   (United States)

^d NATIONAL MARROW DONOR PROGRAM   (United States)

^e UNIVERSITY OF MICHIGAN   (United States)

^f ANTHONY NOLAN RESEARCH INSTITUTE   (United Kingdom)

^g Fred Hutchinson Cancer Research Center   (United States)

^h LERNER RESEARCH INSTITUTE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

GRANULOCYTE COLONY STIMULATING FACTOR; RECOMBINANT GRANULOCYTE COLONY STIMULATING FACTOR;

ADULT; ADVERSE OUTCOME; ARTICLE; AUTOIMMUNE DISEASE; AUTOIMMUNITY; BLOOD VOLUME; BODY WEIGHT; BONE MARROW; BONE MARROW DONATION; CANCER INCIDENCE; CANCER RISK; CEREBROVASCULAR ACCIDENT; COMPARATIVE STUDY; DRUG DOSE REDUCTION; FEMALE; FOLLOW UP; HEMATOPOIETIC STEM CELL; HUMAN; HUMAN EXPERIMENT; MALE; MEDICAL ASSESSMENT; NORMAL HUMAN; ORGAN DONOR; PERIPHERAL BLOOD STEM CELL; PERIPHERAL BLOOD STEM CELL DONATION; PRIORITY JOURNAL; PROSPECTIVE STUDY; THROMBOCYTOPENIA; THROMBOSIS;

ADOLESCENT; ADULT; BONE MARROW; BONE MARROW TRANSPLANTATION; FEMALE; GRANULOCYTE COLONY-STIMULATING FACTOR; HEMATOPOIETIC STEM CELL MOBILIZATION; HEMATOPOIETIC STEM CELLS; HUMANS; MALE; MIDDLE AGED; NEOPLASMS; PERIPHERAL BLOOD STEM CELL TRANSPLANTATION; POSTOPERATIVE COMPLICATIONS; RISK FACTORS; SEVERITY OF ILLNESS INDEX; TISSUE AND ORGAN HARVESTING; TISSUE DONORS; YOUNG ADULT;

EID: 84902150458     PISSN: 00064971     EISSN: 15280020     Source Type: Journal    
DOI: 10.1182/blood-2013-12-542464     Document Type: Article

References (30)

1. Miller JP, Perry EH, Price TH, et al. Recovery and safety profiles of marrow and PBSC donors: experience of the National Marrow Donor Program. Biol Blood Marrow Transplant. 2008; 14(9 Suppl):29-36.
2. King RJ, Confer DL, Greinix HT, et al; Ethics and Clinical Working Groups of World Marrow Donor Association. Unrelated hematopoietic stem cell donors as research subjects. Bone Marrow Transplant. 2011;46(1):10-13.
3. Shaw BE, Ball L, Beksac M, et al; Clinical Working Group; Ethics Working Group of the WMDA. Donor safety: the role of the WMDA in ensuring the safety of volunteer unrelated donors: clinical and ethical considerations. Bone Marrow Transplant. 2010;45(5):832-838.
4. Pulsipher MA, Chitphakdithai P, Logan BR, et al. Acute toxicities of unrelated bone marrow versus peripheral blood stem cell donation: results of a prospective trial from the National Marrow Donor Program. Blood. 2013;121(1):197-206.
5. Parkkali T, Volin L, Sirén MK, Ruutu T. Acute iritis induced by granulocyte colony-stimulating factor used for mobilization in a volunteer unrelated peripheral blood progenitor cell donor. Bone Marrow Transplant. 1996;17(3):433-434. (Pubitemid 26114506)
6. Topcuoglu P, Arat M, Dalva K, Ozcan M. Administration of granulocyte-colony-stimulating factor for allogeneic hematopoietic cell collection may induce the tissue factor-dependent pathway in healthy donors. Bone Marrow Transplant. 2004; 33(2):171-176. (Pubitemid 38180929)
7. Anderlini P, Körbling M, Dale D, et al. Allogeneic blood stem cell transplantation: considerations for donors. Blood. 1997;90(3):903-908. (Pubitemid 27314122)
8. Pulsipher MA, Chitphakdithai P, Miller JP, et al. Adverse events among 2408 unrelated donors of peripheral blood stem cells: results of a prospective trial from the National Marrow Donor Program. Blood. 2009;113(15):3604-3611.
9. Switzer GE, Harrington D, Haagenson M, et al. Health-related quality of life of bone marrow versus peripheral blood stem cell donors: a prespecified subgroup analysis from a phase III RCT-BMTCTN protocol 0201. Biol Blood Marrow Transplant. 2014;20(1):118-127. doi: 10.1016/j.bbmt.2013.10.024. Epub 2013 Nov 1.
10. Kaplan EL, Meier P. Nonparametric estimation from incomplete observations. J Am Stat Assoc. 1958;53:457-481.
11. Buckner CD, Clift RA, Sanders JE, et al. Marrow harvesting from normal donors. Blood. 1984; 64(3):630-634. (Pubitemid 14073480)
12. Stroncek DF, Holland PV, Bartch G, et al. Experiences of the first 493 unrelated marrow donors in the National Marrow Donor Program. Blood. 1993;81(7):1940-1946. (Pubitemid 23101612)
13. Halter J, Kodera Y, Ispizua AU, et al. Severe events in donors after allogeneic hematopoietic stem cell donation. Haematologica. 2009;94(1): 94-101.
14. Hölig K, Kramer M, Kroschinsky F, et al. Safety and efficacy of hematopoietic stem cell collection from mobilized peripheral blood in unrelated volunteers: 12 years of single-center experience in 3928 donors. Blood. 2009;114(18):3757-3763.
15. Anderlini P, Rizzo JD, Nugent ML, Schmitz N, Champlin RE, Horowitz MM; IBMTR Statistical Center of the International Bone Marrow Transplant Registry, Medical College of Wisconcin, Milwaukee, WI, USA; EBMT, Kiel, Germany. Peripheral blood stem cell donation: an analysis from the International Bone Marrow Transplant Registry (IBMTR) and European Group for Blood and Marrow Transplant (EBMT) databases. Bone Marrow Transplant. 2001;27(7): 689-692. (Pubitemid 32409442)
16. Switzer GE, Bruce JG, Harrington D, et al. Healthrelated quality of life of bone marrow versus peripheral blood stem cell donors: a prespecified subgroup analysis from a phase III RCT-BMTCTN protocol 0201. Biol Blood Marrow Transplant. 2014;20(1):118-127.
17. Nasilowska-Adamska B, Perkowska-Ptasinska A, Tomaszewska A, Serwacka A, Marianska B. Acute glomerulonephritis in a donor as a side effect of allogeneic peripheral blood stem cell mobilization with granulocyte colony-stimulating factor. Int J Hematol. 2010;92(5):765-768.
18. Dale DC, Cottle TE, Fier CJ, et al. Severe chronic neutropenia: treatment and follow-up of patients in the Severe Chronic Neutropenia International Registry. Am J Hematol. 2003;72(2):82-93. (Pubitemid 36164341)
19. Hershman D, Neugut AI, Jacobson JS, et al. Acute myeloid leukemia or myelodysplastic syndrome following use of granulocyte colonystimulating factors during breast cancer adjuvant chemotherapy. J Natl Cancer Inst. 2007;99(3): 196-205.
20. Bennett CL, Evens AM, Andritsos LA, et al. Haematological malignancies developing in previously healthy individuals who received haematopoietic growth factors: report from the Research on Adverse Drug Events and Reports (RADAR) project. Br J Haematol. 2006;135(5): 642-650. (Pubitemid 44674074)
21. Makita K, Ohta K, Mugitani A, et al. Acute myelogenous leukemia in a donor after granulocyte colony-stimulating factor-primed peripheral blood stem cell harvest. Bone Marrow Transplant. 2004;33(6):661-665. (Pubitemid 38455931)
22. Nagler A, Korenstein-Ilan A, Amiel A, Avivi L. Granulocyte colony-stimulating factor generates epigenetic and genetic alterations in lymphocytes of normal volunteer donors of stem cells. Exp Hematol. 2004;32(1):122-130. (Pubitemid 38064408)
23. Hirsch B, Oseth L, Cain M, et al. Effects of granulocyte-colony stimulating factor on chromosome aneuploidy and replication asynchrony in healthy peripheral blood stem cell donors. Blood. 2011;118(9):2602-2608.
24. Anderlini P, Chan FA, Champlin RE, Körbling M, Strom SS. Long-term follow-up of normal peripheral blood progenitor cell donors treated with filgrastim: no evidence of increased risk of leukemia development. Bone Marrow Transplant. 2002;30(10):661-663. (Pubitemid 35446647)
25. Jeger A, Favre G, Lutz JM, et al. Tumor incidence in related hematopoietic stem cell donors. Bone Marrow Transplant. 2011;46(9):1240-1244.
26. Cavallaro AM, Lilleby K, Majolino I, et al. Three to six year follow-up of normal donors who received recombinant human granulocyte colony-stimulating factor. Bone Marrow Transplant. 2000;25(1):85-89. (Pubitemid 30093161)
27. de la Rubia J, de Arriba F, Arbona C, et al. Follow-up of healthy donors receiving granulocyte colony-stimulating factor for peripheral blood progenitor cell mobilization and collection. Results of the Spanish Donor Registry. Haematologica. 2008;93(5): 735-740. (Pubitemid 351669314)
28. Kodera Y, Yamamoto K, Harada M, et al. PBSC collection from family donors in Japan: a prospective survey. Bone Marrow Transplant. 2014;49(2):195-200.
29. Huhn RD, Yurkow EJ, Tushinski R, et al. Recombinant human interleukin-3 (rhIL-3) enhances the mobilization of peripheral blood progenitor cells by recombinant human granulocyte colony-stimulating factor (rhG-CSF) in normal volunteers. Exp Hematol. 1996;24(7): 839-847. (Pubitemid 26227615)
30. Tigue CC, McKoy JM, Evens AM, Trifilio SM, Tallman MS, Bennett CL. Granulocyte-colony stimulating factor administration to healthy individuals and persons with chronic neutropenia or cancer: an overview of safety considerations from the Research on Adverse Drug Events and Reports project. Bone Marrow Transplant. 2007; 40(3):185-192. (Pubitemid 47108460)